Bristol Myers Squibb Co (BMY): Operating Cash Flow
$14.16B
Year ended 2025-12-31
$12.78B
Trailing 12 months to 2026-06-30
+2.7%
3-year compound annual growth
+0.1%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.16B | -6.8% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $15.19B | +9.6% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $13.86B | +6.1% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $13.07B | -19.4% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $16.21B | +15.3% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $14.05B | +71.2% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $8.21B | +16.2% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $7.07B | n/c | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $5.28B | +72.5% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $3.06B | +45.3% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $2.10B | n/c | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $3.15B | -11.2% | 2017-02-21, From 2014-01-01 |
| 2013-12-31 | $3.54B | -48.9% | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | $6.94B | +43.4% | 2015-02-13, From 2012-01-01 |
| 2011-12-31 | $4.84B | +7.8% | 2014-02-14, From 2011-01-01 |
| 2010-12-31 | $4.49B | +10.5% | 2013-02-15, From 2010-01-01 |
| 2009-12-31 | $4.07B | +9.7% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $3.71B | +17.6% | 2011-02-18, From 2008-01-01 |
| 2007-12-31 | $3.15B | n/a | 2010-02-19, From 2007-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $19.03B | +1.2% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
Compare BMY, ABT, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗